LIVE Stocks surge after Trump retakes the White House. Follow our live blog. Frankfurt - Delayed Quote ? EUR Vicore Pharma Holding AB (publ) (6Y4.F) Follow Compare 0.6290 -0.0040 (-0.63%) As of 8:13 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Increase of Number of Shares and Votes in Vicore Pharma STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise ... ACCESSWIRE ? 5 months ago VICO.ST -0.63% Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO) Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment. The therapy was safe and well tolerated with no treatment-related ... ACCESSWIRE ? 5 months ago VICO.ST -0.63% Vicore Expands and Strengthens its Board of Directors STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin ... ACCESSWIRE ? 5 months ago VICO.ST -0.63% Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ) STOCKHOLM, SE / ACCESSWIRE / May 7, 2024 / Vicore Pharma Holding (STO:VICO) The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 7 May 2024. Adoption of income statement and balance ... ACCESSWIRE ? 5 months ago VICO.ST -0.63% Interim Report January-March 2024 STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists ... ACCESSWIRE ? 6 months ago VICO.ST -0.63% Vicore to Present at Upcoming Investor Conferences STOCKHOLM, SE / ACCESSWIRE / April 12, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, April 12, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), ... ACCESSWIRE ? 6 months ago VICO.ST -0.63% Notice of Annual General Meeting of Vicore Pharma Holding AB (publ) STOCKHOLM, SWEDEN / ACCESSWIRE / April 4, 2024 / Vicore Pharma Holding (STO:VICO) The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 ("Vicore Pharma" or the "Company"), with its registered offices in Stockholm, are summoned ... ACCESSWIRE ? 6 months ago VICO.ST -0.63% Vicore Announces Presentations at the 2024 American Thoracic Society International Conference STOCKHOLM, SWEDEN / ACCESSWIRE / March 28, 2024 / Vicore Pharma Holding (STO:VICO) Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPF Additional presentations ... ACCESSWIRE ? 7 months ago VICO.ST -0.63% Vicore Publishes the Annual Report for 2023 STOCKHOLM, SWEDEN / ACCESSWIRE / March 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, March 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), ... ACCESSWIRE ? 7 months ago VICO.ST -0.63% Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis STOCKHOLM, SE / ACCESSWIRE / March 19, 2024 / Vicore Pharma Holding (STO:VICO) AlmeeTM is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis (PF). AlmeeTM has shown effectiveness in reducing ... ACCESSWIRE ? 7 months ago VICO.ST -0.63% Year-end Report 2023 STOCKHOLM, SWEDEN / ACCESSWIRE / February 28, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, February 28, 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor ... ACCESSWIRE ? 8 months ago VICO.ST -0.63% Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan STOCKHOLM, SWEDEN / ACCESSWIRE / February 9, 2024 / Vicore Pharma Holding (STO:VICO) C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF) Vicore to receive USD 10 million upfront and is entitled to up ... ACCESSWIRE ? 8 months ago VICO.ST -0.63% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return 6Y4.F OMX Stockholm 30 Index YTD -50.86% +6.46% 1-Year -42.82% +20.05% 3-Year -64.58% +9.82%